News

Date
Title
Sort By:
12/18/24
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
11/06/24
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/10/24
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
10/03/24
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
08/27/24
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
08/08/24
SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
07/23/24
SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
05/08/24
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
04/30/24
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
04/09/24
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)